Esben Andreas Carlsen1,2, Camilla Bardram Johnbeck1,2, Mathias Loft1,2, Andreas Pfeifer1,2, Peter Oturai1,2, Seppo W Langer2,3, Ulrich Knigge2,4, Claes Nøhr Ladefoged1,2, Andreas Kjaer5,2. 1. Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Department of Biomedical Sciences, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark. 2. ENETS Neuroendocrine Tumor Center of Excellence, Rigshospitalet, Copenhagen, Denmark. 3. Department of Oncology, Rigshospitalet, Copenhagen, Denmark; and. 4. Departments of Clinical Endocrinology and Surgical Gastroenterology, Rigshospitalet, Copenhagen, Denmark. 5. Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Department of Biomedical Sciences, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark; akjaer@sund.ku.dk.
Abstract
Patients with neuroendocrine neoplasms (NENs) have heterogeneous somatostatin receptor expression, with highly differentiated lesions having higher expression. Receptor expression of the total tumor burden may be visualized by somatostatin receptor imaging, such as with 64Cu-DOTATATE PET/CT. Assessment of maximal lesion uptake is associated with progression-free survival (PFS) but not overall survival (OS). We hypothesized that the lesion with the lowest, rather than the highest, 64Cu-DOTATATE uptake would be more prognostic, and we developed a semiautomatic method for evaluating this hypothesis. Methods: Patients with NENs underwent 64Cu-DOTATATE PET/CT. A standardized semiautomatic tumor delineation method was developed and used to identify the lesion with the lowest uptake, that is, with the lowest SUVmean Additionally, we assessed total tumor volume derived from the semiautomatic tumor delineation. Kaplan-Meier and Cox regression analyses were used to determine whether there was any association with OS and PFS. Results: In 116 patients with NENs, median PFS (95% CI) was 23 mo (range, 20-31 mo) and median OS was 85 mo (range, 68-113 mo). Minimum SUVmean and total tumor volume were significantly associated with PFS and OS in univariate Cox regression analyses, whereas SUVmax was significant only for PFS. In multivariate Cox analyses, both minimum SUVmean and total tumor volume remained statistically significant. Minimum SUVmean and total tumor volume were then dichotomized by their median, and patients were categorized into 4 groups: high or low total tumor volume and high or low minimum SUVmean Patients with a low total tumor volume and high minimum SUVmean had a hazard ratio of 0.32 (95% CI, 0.20-0.51) for PFS and 0.24 (95% CI, 0.13-0.43) for OS, both with P values of less than 0.001 (reference: high total tumor volume and low minimum SUVmean). Conclusion: We propose a standardized semiautomatic tumor delineation method to identify the lesion with the lowest 64Cu-DOTATATE uptake and total tumor volume. Assessment of the lowest, rather than the highest, lesion uptake greatly increases prognostication by 64Cu-DOTATATE PET/CT. Combining lesion uptake and total tumor volume, we derived a novel prognostic classification system for patients with NENs.
Patients with neuroendocrine neoplasms (NENs) have heterogeneous somatostatin receptor expression, with highly differentiated lesions having higher expression. Receptor expression of the total tumor burden may be visualized by somatostatin receptor imaging, such as with 64Cu-DOTATATE PET/CT. Assessment of maximal lesion uptake is associated with progression-free survival (PFS) but not overall survival (OS). We hypothesized that the lesion with the lowest, rather than the highest, 64Cu-DOTATATE uptake would be more prognostic, and we developed a semiautomatic method for evaluating this hypothesis. Methods: Patients with NENs underwent 64Cu-DOTATATE PET/CT. A standardized semiautomatic tumor delineation method was developed and used to identify the lesion with the lowest uptake, that is, with the lowest SUVmean Additionally, we assessed total tumor volume derived from the semiautomatic tumor delineation. Kaplan-Meier and Cox regression analyses were used to determine whether there was any association with OS and PFS. Results: In 116 patients with NENs, median PFS (95% CI) was 23 mo (range, 20-31 mo) and median OS was 85 mo (range, 68-113 mo). Minimum SUVmean and total tumor volume were significantly associated with PFS and OS in univariate Cox regression analyses, whereas SUVmax was significant only for PFS. In multivariate Cox analyses, both minimum SUVmean and total tumor volume remained statistically significant. Minimum SUVmean and total tumor volume were then dichotomized by their median, and patients were categorized into 4 groups: high or low total tumor volume and high or low minimum SUVmean Patients with a low total tumor volume and high minimum SUVmean had a hazard ratio of 0.32 (95% CI, 0.20-0.51) for PFS and 0.24 (95% CI, 0.13-0.43) for OS, both with P values of less than 0.001 (reference: high total tumor volume and low minimum SUVmean). Conclusion: We propose a standardized semiautomatic tumor delineation method to identify the lesion with the lowest 64Cu-DOTATATE uptake and total tumor volume. Assessment of the lowest, rather than the highest, lesion uptake greatly increases prognostication by 64Cu-DOTATATE PET/CT. Combining lesion uptake and total tumor volume, we derived a novel prognostic classification system for patients with NENs.
Authors: Andreas Pfeifer; Ulrich Knigge; Tina Binderup; Jann Mortensen; Peter Oturai; Annika Loft; Anne Kiil Berthelsen; Seppo W Langer; Palle Rasmussen; Dennis Elema; Eric von Benzon; Liselotte Højgaard; Andreas Kjaer Journal: J Nucl Med Date: 2015-05-07 Impact factor: 10.057
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Ho Seong Kim; Joon Young Choi; Dong Wook Choi; Ho Yeong Lim; Joo Hee Lee; Sun Pyo Hong; Young Seok Cho; Kyung-Han Lee; Byung-Tae Kim Journal: Nucl Med Mol Imaging Date: 2014-02-07
Authors: Amit Tirosh; Georgios Z Papadakis; Corina Millo; Dima Hammoud; Samira M Sadowski; Peter Herscovitch; Karel Pacak; Stephen J Marx; Lily Yang; Pavel Nockel; Jasmine Shell; Patience Green; Xavier M Keutgen; Dhaval Patel; Naris Nilubol; Electron Kebebew Journal: Gastroenterology Date: 2017-11-16 Impact factor: 22.682
Authors: Walter Koch; Christoph J Auernhammer; Julia Geisler; Christine Spitzweg; Clemens C Cyran; Harun Ilhan; Peter Bartenstein; Alexander R Haug Journal: Mol Imaging Date: 2014 Impact factor: 4.488
Authors: David L Chan; Elizabeth Bernard; Geoffrey Schembri; Paul Roach; Meaghan Johnson; Nick Pavlakis; Stephen J Clarke; Dale Bailey Journal: Neuroendocrinology Date: 2019-11-12 Impact factor: 4.914
Authors: Robert Seifert; Ken Herrmann; Jens Kleesiek; Michael Schäfers; Vijay Shah; Zhoubing Xu; Guillaume Chabin; Sasa Grbic; Bruce Spottiswoode; Kambiz Rahbar Journal: J Nucl Med Date: 2020-04-24 Impact factor: 10.057